Abstract
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
Original language | English |
---|---|
Pages (from-to) | 820-827 |
Number of pages | 8 |
Journal | Cancer Investigation |
Volume | 28 |
Issue number | 8 |
DOIs | |
Publication status | Published - Sep 2010 |
Keywords
- Cisplatin
- Esophageal cancer
- Paclitaxel
- Preoperative chemoradiotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)